This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grover, A. Articles by Alexander, H. R. Search for Related Content PubMed PubMed Citation Articles by Grover, A. Articles by Alexander, H. R., Jr.

The Past Decade of Experience With Isolated Hepatic Perfusion

Surgical Metabolism Section, Surgery Branch, Center for Cancer Research National Cancer Institute, Bethesda, Maryland, USA

Correspondence: H. Richard Alexander, Jr., M.D., Head, Surgical Metabolism Section, National Cancer Institute/NIH, 10 Center Drive, Building 10, Room 2B07, Bethesda, Maryland 20892-1502, USA. Telephone: 301-496-2195; Fax: 301-402-1788; e-mail: Richard_Alexander{at}nih.gov

Metastatic or primary unresectable cancers confined to the liver are the sole or life-limiting component of disease for many patients with colorectal cancer, ocular melanoma, neuroendocrine tumors, or primary colangio- or hepatocellular carcinomas. Regional treatment strategies including infusional chemotherapy and local ablative therapy are under investigation, but have limitations with respect to the clinical conditions under which they can be employed. Isolated hepatic perfusion (IHP) was first clinically applied over 40 years ago, but because of its technical complexity, the attendant potential morbidity, and the lack of documented efficacy, it has not enjoyed consistent or widespread evaluation. In light of the antitumor activity with isolated limb perfusion with tumor necrosis factor (TNF) and melphalan in patients with unresectable extremity sarcoma or in transit melanoma, this regimen has been administered via IHP at several centers worldwide for patients with unresectable liver cancers. IHP with TNF and melphalan can result in significant regression of advanced refractory cancers from multiple histologies confined to the liver. Patient selection is important to ensure good results with minimal morbidity and mortality. Work to define the appropriate clinical groups is ongoing at many clinical centers.

Key Words. Liver metastases • Primary hepatic neoplasms • Colorectal cancer • Ocular melanoma • Isolation perfusion • Regional chemotherapy • Hyperthermia

This article has been cited by other articles:

				K. V. Sharma, J. E. Gould, J. W. Harbour, G. P. Linette, T. K. Pilgram, P. N. Dayani, and D. B. Brown Hepatic Arterial Chemoembolization for Management of Metastatic Melanoma Am. J. Roentgenol., January 1, 2008; 190(1): 99 - 104. [Abstract] [Full Text] [PDF]